The impact of home treatment and self-administration of omalizumab on chronic urticaria
Background: Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very...
Main Authors: | Anne Christine Wiuff, MBBS, Malthe Alexander Knudsgaard Wiis, MBBS, Sofine Heilskov, MD, Anne Sofie Frølunde, MD, Jennifer Astrup Sørensen, MD, Mette Deleuran, MD, DMSc, Simon Francis Thomsen, MD, PhD, DMSc, Christian Vestergaard, MD, PhD, DMSc |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455122001016 |
Similar Items
-
Expert consensus on the use of omalizumab in chronic urticaria in China
by: Zuotao Zhao, MD, PhD, et al.
Published: (2021-11-01) -
Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: A real-world longitudinal study
by: Hyun-Young Lee, PhD, et al.
Published: (2024-05-01) -
Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
by: Nadja Højgaard Pedersen, et al.
Published: (2023-07-01) -
Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis
by: Yuxu Yao, MD, et al.
Published: (2024-05-01) -
Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis
by: Haiyan Qin, MD, et al.
Published: (2024-04-01)